TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06739395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-Hziy 180 MG
Description: Usage and dosage: The recommended dosage is 10 mg/kg, administered intravenously every 21 days as a treatment cycle on the 1st and 8th days, and continued until disease progression or unacceptable toxicity occurs. The dosage of this product should not exceed 10 mg/kg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study: NCT04658069

Intervention type: OTHER
Intervention: no specific interventions
Description: no specific interventions
Study: NCT05647993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Injection [Zithromax]
Description: Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefazolin
Description: All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Intravenous Solution
Description: For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
Study: NCT01089192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04654507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04728945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung recruitment
Description: Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ventilatory management
Description: After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ventilatory management
Description: After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)
Study: NCT04428658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental video visits
Description: Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual quarterly visits with the UCD Pediatric Diabetes Clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Usual quarterly visits with the UCD Pediatric Diabetes Clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Usual quarterly visits with the UCD Pediatric Diabetes Clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental remote monitoring
Description: Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
Study: NCT06637371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 691
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 691
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 691
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection
Study: NCT05712200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abelacimab
Description: Abelacimab provided as liquid in vial (150 mg/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab
Study: NCT06291376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive ravulizumab via weight-based intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via weight-based IV infusion.
Study: NCT04372108

Intervention type: DRUG
Intervention: Ustekinumab
Description: Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.

Intervention type: DRUG
Intervention: Other Biologic Therapies
Description: Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
Study: NCT06320990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20mg
Description: Tamoxifen is a nonsteroidal antiestrogen for oral administration.
Study: NCT02531880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir
Description: Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
Study: NCT06739395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Usage and dosage: For patients weighing less than 60kg, the recommended daily dose of lenvatinib is 8mg once a day; For patients weighing ≥ 60kg, the recommended daily dose of lenvatinib is 12mg once daily. Lunvatinib should be taken at a fixed time every day, on an empty stomach or with food.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study: NCT05643976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.
Study: NCT06561373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm & Alert yoga and mindfulness
Description: The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
Study: NCT06480032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction band
Description: Blood Flow Restriction (BFR) band operate by partially occluding arterial blood flow to distal structures, but more significantly impeding venous outflow from under the cuff, thereby also hindering venous return. The compression of vasculature proximal to the skeletal muscle leads to inadequate oxygen supply (hypoxia) within the muscle tissue, resulting in a localized hypoxic environment. Additionally, the reduction in venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-Blood Flow Restriction band
Description: The Occlusion Band/Blood Flow Restriction (BFR) band functions by partially restricting arterial blood flow to distal structures, with a more pronounced effect on venous outflow from under the cuff, thereby impeding venous return. Proximal compression of the vasculature leads to inadequate oxygen supply (hypoxia) in the skeletal muscle tissue. Additionally, reduced venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks, facilitating targeted exercise training and rehabilitation.
Study: NCT04717960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal submucosal injection of platelet rich plasma
Description: * The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months
Study: NCT06562049

Intervention type: RADIATION
Intervention: musculoskeletal ultrasound
Description: musculoskeletal ultrasound on both hands
Study: NCT06056284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises and sleep hygiene training
Description: Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
Study: NCT06739395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Pill
Description: Usage and dosage: In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.The dosage for combined use will be adaptively adjusted by the researcher.~Administration method: Oral treatment once a day, with a cycle of 28 days.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study: NCT06468371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine Agonist (Ropinirole)
Description: Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excercise training
Description: Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
Study: NCT04751500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Description: Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expectant management
Description: Leaving the retained pregnancy tissue alone to pass by itself

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Giving medications to contract the womb to pass the retained pregnancy tissue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical management
Description: Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
Study: NCT05004675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inclisiran
Description: 284 mg
Study: NCT06562049

Intervention type: RADIATION
Intervention: musculoskeletal ultrasound
Description: musculoskeletal ultrasound on both hands

Intervention type: RADIATION
Intervention: musculoskeletal ultrasound
Description: musculoskeletal ultrasound on both hands
Study: NCT06524921

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental pulpectomy using metapex
Description: Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental pulpectomy using biodentine
Description: Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
Study: NCT05344053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based precise management
Description: The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard community-based management
Description: The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
Study: NCT05305248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
Study: NCT06253403

Intervention type: BEHAVIORAL
Intervention: psychotherapy
Description: psychotherapy related to sexual intervention
Study: NCT05963230

Intervention type: OTHER
Intervention: Ultrasound scans
Description: Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
Study: NCT05548855

Intervention type: PROCEDURE
Intervention: Heart Transplant
Description: Patients who have undergone a heart transplant as standard of care (SOC) procedure

Intervention type: DEVICE
Intervention: Cardiac Assistive Device
Description: Patients who have undergone a placement of a cardiac assistive device
Study: NCT04677569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALIS
Description: Inhalation via nebulization over approximately 6 to 15 minutes
Study: NCT05710172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Mirror Therapy
Description: 21 days, up to 3 hours per day intervention

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auditory Mirror Therapy
Description: 21 days, up to 3 hours per day intervention
Study: NCT05611736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold saline
Description: After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
Study: NCT04863716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block will be administered before the surgery.
Study: NCT05611736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
Study: NCT05130983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Study: NCT06181500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based multicomponent exercise intervention program
Description: A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
Study: NCT06091605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation around dental implants.
Description: Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation around dental implants.
Description: Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.